Citi Downgrades SenoRx (SENO) to Hold
SENO Hot Sheet
Rating Summary:0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Citi downgrades SenoRx (Nasdaq: SENO) from Buy to Hold. PT increased by $1 to $11.
To see all the upgrades/downgrades on shares of SENO, visit our Analyst Ratings page.
SenoRx, Inc. develops, manufactures and sells medical devices that are used in the diagnosis and treatment of breast cancer.
To see all the upgrades/downgrades on shares of SENO, visit our Analyst Ratings page.
SenoRx, Inc. develops, manufactures and sells medical devices that are used in the diagnosis and treatment of breast cancer.
You May Also Be Interested In
- UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
- Canaccord Genuity Maintains a 'Hold' on Tiffany & Co. (TIF); Cutting PT and Estimates
- Barclays Lowers PT and Estimates on Royal Bank of Canada (RY); Coming Off The Bandwagon
Create E-mail Alert Related Categories
DowngradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
